Status:
COMPLETED
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Seasonal Allergic Conjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs an...
Eligibility Criteria
Inclusion
- Subjects who are diagnosed with acute SAC and experience at least grade 4 ocular itching and at least grade 2 bulbar conjunctival injection (redness) in each eye due to seasonal allergy at Visit 1.
Exclusion
- Subjects who have a known hypersensitivity to the study medications or their components or contraindications to ocular corticosteroids.
- Subjects who use any of the disallowed medications throughout the duration of the study and during the period indicated prior to Visit 1.
- Subjects who have intraocular pressure (IOP) greater than 21 mm Hg in either eye or any type of glaucoma.
- Subjects who have a history of any severe/serious ocular pathology or medical condition that could result in the subject's inability to complete the study or affect the subject's safety or trial parameters.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01435460
Start Date
August 1 2010
End Date
May 1 2011
Last Update
March 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bausch & Lomb Singapore
Singapore, Singapore, Singapore, 556741